Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

Abstract: The present invention provides process for preparation of Crystalline Erlotinib HCl (I) Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2?° peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40, 20.65, 21.86, 23.5, 31.80, 32.13, 32.80, 34.40±0.20 2?°, DSC isotherm comprising the endothermic peaks ranging between 213 to 217° C. (Peak ?1) and 225 to 235° C. (Peak ?2) and IR absorption characteristic peaks at approximately 3278 cm?1, 1948 cm?1, 1871 cm?1, 1632 cm?1, 1164 cm?1, 1024 cm?1, 940 cm?1 and 742 cm?1 useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment cancer.

Abstract: This invention provides compounds of the formula I: and their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.

Abstract: There is provided a compound having Formula I In the formula: R1 can be alkyl, aryl, alkylaryl, or deuterated analogs thereof; R2 can be alkyl or deuterated alkyl; R3 can be H, D, aryl, or deuterated aryl; and R4-R6 are the same or different and can be H, D, alkyl, or deuterated alkyl. In the formula, at least one of the following conditions is met: (i) R1 is a secondary alkyl, a tertiary alkyl, aryl, alkylaryl, or deuterated analog thereof; (ii) R3 is aryl or deuterated aryl; (iii) at least one of R3-R6 is D.

Abstract: Present disclosure discloses the commercially viable process for the preparation of Deferasirox and its polymorph with. Disclosed process involves the preparation of Deferasirox via metal salt of the corresponding intermediate and deferasirox metal salt.

Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.

Abstract: The present invention relates to a two-stage preparation process for an organic UV absorber that has a (meth)acrylate group in the molecule and which as a result is particularly suitable for curable UV protective coatings.

Abstract: The present invention relates to a method for preparing TDI (toluene diisocyanate) isocyanurate by using TDI, monohydric alcohol, solvent, antioxidant, catalyst and termination agent as the raw materials. The properties of the isocyanurate are improved by the process comprising the modification by monohydric alcohol and addition of the catalyst and solvent in several stages at an appropriate temperature. By adding the catalyst and solvent in batches at the condition of controlling both NCO % and the viscosity in the preparation process, and adjusting the solid content at each step, the resulting TDI isocyanurate has low content of free TDI, high xylene tolerance, small product color number, and high performance stability, which makes the product obtained by the isocyanurate have good application properties such as the drying, polishing and extinction properties of coating film, and such isocyanurate has good compatibility with other components.

Abstract: A propylene oxide separation system that comprises a distillation column, a decanter, and water wash system. The distillation column is configured to receive a crude propylene oxide stream, discharge an impurity stream that comprises methanol and water, and discharge a bottoms stream that comprises a majority of the propylene oxide entering in the crude propylene oxide stream. The decanter is configured to receive at least a portion of the impurity stream and a hydrocarbon solvent to provide for formation in the decanter of an organic phase and an aqueous phase. The organic phase comprises propylene oxide and hydrocarbon solvent, and is sent to the distillation column. The aqueous phase comprises a majority weight percent of the methanol and the water entering in the impurity stream. The water wash system is configured to receive and purge the aqueous phase from the propylene oxide separation system.

Abstract: Methods for making epoxidized fatty acid alkyl esters. Such epoxidized fatty acid alkyl esters can be prepared by epoxidizing a natural oil with an acid and a peroxide. Residual acid in the epoxidized natural oil is not neutralized, such as with a base, prior to esterification to produce the epoxidized fatty acid alkyl esters. Epoxidized fatty acid alkyl esters can be employed in plasticizers, either alone or in combination with other plasticizers, such as epoxidized natural oils. Such plasticizers in turn may be used in the formation of polymeric compositions.

Abstract: A process of preparing a compound of formula (I) wherein R represents a linear or branched C5 alkyl group, as well as the use of such compounds in a fragrant and/or flavoring composition.

Abstract: A method for producing a product that comprises glycerol ketal of ethyl levulinate or propylene glycol ketal of ethyl levulinate comprises reacting either glycerol or propylene glycol with ethyl levulinate in the presence of a homogenous or heterogeneous catalyst system in a reactor system. The ethyl levulinate and either glycerol or propylene glycol are heated to remove water, polyol, and excess ethyl levulinate. The excess ethyl levulinate and polyol is recycled back to the reactor. The product is distilled in a specific fashion and optionally treated by means of a stabilizing agent or acid species removal bed, to obtain a composition comprising glycerol ketal of ethyl levulinate or propylene glycol ketal of ethyl levulinate wherein the composition comprises less than or equal to about 2 wt % contaminants.

Abstract: A liquid crystal medium having stability to heat, light and so forth, a wide liquid crystal phase temperature range, a low driving voltage and a small permittivity and exhibiting an optically isotropic liquid crystal phase is described. An optical device or the like having a short response time, a large contrast ratio, a low driving voltage and a small permittivity is also described. The liquid crystal composition contains an achiral component (T) and a chiral agent, and exhibits an optically isotropic liquid crystal phase. The achiral component (T) includes at least one compound represented by formula (1): wherein, for example, R1 is alkyl having 1 to 12 carbons, A1 and A2 are 1,4-phenylene, Z1 and Z2 are single bonds, Z3 is —COO— or —CF2O—, L11 is hydrogen, fluorine or chlorine, Y1 is fluorine, chlorine, —CF3 or —OCF3, n1 and n2 are each independently 0 or 1, and n1+n2?1.

Abstract: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.

Abstract: The present invention relates to chemical compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (?7 nAChR).

Abstract: Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Abstract: The present invention provides a new group of protein kinase inhibitors, aminopyrimidine derivatives, and pharmaceutically acceptable salts thereof that are useful for treating cell proliferative disease and disorder such as cancer and immune disease. The present invention provides methods for synthesizing and administering the protein kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the protein kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefore. The invention also provides useful intermediates generated during the syntheses of the aminopyrimidine derivatives.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

Abstract: Disclosed is a method for preparing avanafil (I) by using cytosine as the starting material. The preparation steps comprise: using cytosine as the raw material, and enabling the cytosine to react with side chain 3-chlorine-4-methoxybenzyl halogen, N-(2-methylpyrimidine)methanamide and S-hydroxymethyl pyrrolidine, to prepare the target product avanafil (I). For the preparation method, the raw material is easily obtained, and the process is simple, economical, and environmentally friendly, so the method meets the requirement of industrial boost.

Abstract: Piperidine compounds and pharmaceutically useful salts thereof, a pharmaceutical composition including an effective amount of the racemic or enantiomerically enriched piperidine compounds to treat gastrointestinal diseases, and a method of treating gastrointestinal diseases in a mammal are provided.

Abstract: The invention provides pyridyl-hydfazones of Formula I, or pharmaceutically acceptable salts, esters, solvates, isprriers and prodrugs thereof as well as pharmaceutical compositions containing these compounds for use in the prophylactic and/or therapeutic treatment of tuberculosis and related diseases, such as, diseases caused by nontuberculous mycobacteria and/or caused by Micobacterium leprae.

Abstract: The present invention relates to an improved process for the preparation of Oxazolidinone derivatives. More specifically, the present invention relates to an improved process for preparing (S)-N-[[3-[3-fluoro-4-[4-morpholinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]phthalimide, an intermediate used in the preparation of Oxazolidinone derivatives.

Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.

Abstract: The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, Alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R9, R10 and R11 are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The present invention is directed to compounds and forms and pharmaceutical compositions thereof useful for treating a viral infection, or for affecting viral activity by modulating viral replication.

Abstract: The present disclosure relates to compounds that act as agonists of, or otherwise modulate the activity of, GPR131 and to their use in the treatment of various diseases. In particular embodiments, the structure of the compounds is given by Formula I: wherein the variables are as described herein. Related compositions, formulations and methods for the preparation of compounds of formula I are also described.

Abstract: In one aspect, the invention relates to compounds having the formula I: where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

Abstract: The present disclosure provides oxidized berbine derivatives, processes for their preparation, and methods of using the oxidized berbine derivatives.

Abstract: Provided is a compound capable of effectively control worst weeds of higher leaf stages that present practical problems. A specific pyrazolylpyrazole derivative of formula (I) is disclosed that is able to solve the above-mentioned problems.

Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-KB activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.

Abstract: The invention relates to fluorinated compounds and their use as integrin receptor antagonists. Novel fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives and pharmaceutically acceptable salts or solvates thereof and their use are described.

Abstract: The present invention relates to substituted fused tricyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by JAK activity. The compounds of the present invention are useful in the treatment, prevention or suppression of diseases and disorders mediated by JAK activity.

Abstract: Crystalline form, Form T1H1.5-4, of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl -1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound (I)) is provided. Also provided is a pharmaceutical composition and an oral dosage form comprising Form T1H1.5-4 of Compound (I) as well as a method of using the Form T1H1.5-4 of Compound for the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.

Abstract: Crystalline form, Form HI.5-4, of N,N-di-cyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide, (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising Form HI.5-4 of Compound I as well as a method of using the Form HI.5-4 of Compound I in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.

Abstract: The present invention provides xanthine-substituted alkynyl carbamates/reverse carbamates and derivatives thereof and pharmaceutical compositions containing the same that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

Abstract: The present invention provides a process for the preparation of linagliptin, a compound of Formula I, the process comprising deprotecting a compound of Formula II wherein R1 and R2 together with the nitrogen to which they are attached form a phthalimido group, wherein the aromatic ring of the phthalimido group is substituted with one or more R3 substituents selected from the group consisting of halogen, alkyl, nitro and amino; or R1 is H and R2 is selected from the group consisting of trialkylsilyl, 2-trialkylsilylethoxycarbamates, acetyl, trihaloacetyl, 9-fluorenylmethoxycarbonyl, trityl, alkylsulfonyl, arylsulfonyl, diphenylphosphine and sulfonylethoxycarbonyl.

Abstract: The invention concerns a paralytic shellfish poison for the treatment of itching in a human being or another mammal.

Abstract: Disclosed are chemical entities that inhibit Uba6, each of which is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R*1 is —H or —CH3; and Y is Formula (II) or Formula (III), wherein R2 is —H, —CH3 or C1-4 alkyloxycarbonyl; and RS7.1, RS7.2 and RS8.1 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.

Abstract: Provided is a compound capable of effectively control worst weeds of higher leaf stages that present practical problems. A specific pyrazolylpyrazole derivative of formula (1) is disclosed that is able to solve the above-mentioned problems.

Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Abstract: The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can be alkaloids and, more particularly, the tertiary amines can be opioids. In specific embodiments, the present disclosure provides methods for use in processes for the synthesis of naloxone and naltrexone from oripavine.

Abstract: In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of 5 treating or preventing diseases or conditions related to BDNF and TrkB activity, such as depression, stroke, Rett syndrome, Parkinson's disease, and Alzheimer's disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein to a subject in need thereof.

Abstract: The invention recites an improved process for preparing spirocyclic isoxazoline derivatives of Formula (1) wherein “*”, R1a, R1b, and R1c are as described herein.

Abstract: This invention relates to compounds of formula I, their use as allosteric modulators of mGluR5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for the treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction, such as schizophrenia or cognitive decline, dementia or cognitive impairment, or other pathologies that can be related directly or indirectly to glutamate dysfunction.

Abstract: Compounds of the formula V: or a pharmaceutically acceptable salt thereof, wherein, R2 is optionally substituted phenyl, optionally substituted pyridin-2-yl or optionally substituted thienyl, and R3, R4, R5, R6 and R13 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: The present invention relates to a crystalline form III and a crystalline form IV of N-benzoyl staurosporine.

Abstract: Structure and luminescence properties of a new Cu-Cyteamine (Cu-Cy) crystal material are provided. The crystal structure of the Cu-Cy is determined by single crystal X-ray diffraction. It is found that the compound crystallizes in the monoclinic space group C2/c and cell parameters are a=7.5510(4) ?, b=16.9848(7) ?, c=7.8364(4) ?, ?=104.798(3)°. The new Cu-Cy crystal material of the invention is also useful for treatment of cancer.